

# Tumor antigen-specific T helper cells in cancer immuni

Cancer Immunology, Immunotherapy

54, 721-728

DOI: [10.1007/s00262-004-0653-2](https://doi.org/10.1007/s00262-004-0653-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. <i>International Journal of Oncology</i> , 1992, 34, 173.	1.4	6
2	A Novel Strategy for the Discovery of MHC Class II "Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope. <i>Cancer Research</i> , 2005, 65, 10068-10078.	0.4	37
3	Strategies of Tumor Immune Evasion. <i>BioDrugs</i> , 2005, 19, 347-354.	2.2	120
4	Continuous Presence of Th1 Conditions Is Necessary for Longer Lasting Tumor-Specific CTL Activity in Stimulation Cultures With PBL. <i>Human Immunology</i> , 2005, 66, 884-891.	1.2	17
5	Cancer vaccines: The next generation. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005, 2, 323-330.	0.5	2
6	Chemical Conjugate TMV~Peptide Bivalent Fusion Vaccines Improve Cellular Immunity and Tumor Protection. <i>Bioconjugate Chemistry</i> , 2006, 17, 1330-1338.	1.8	53
7	li-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1311-1321.	1.4	24
8	Allogeneic hematopoietic stem cell transplantation for malignant disease: How to prevent graft-versus-host disease without jeopardizing the graft-versus-tumor effect?. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 25-30.	0.5	2
9	The tumor microenvironment in the post-PAGET era. <i>Cancer Letters</i> , 2006, 242, 1-10.	3.2	135
10	A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. <i>Vaccine</i> , 2006, 24, 5862-5871.	1.7	25
11	Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. <i>International Journal of Experimental Pathology</i> , 2006, 87, 163-176.	0.6	75
12	T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. <i>Leukemia</i> , 2006, 20, 2015-2024.	3.3	14
13	Molecular and functional analysis using live cell microarrays. <i>Current Opinion in Chemical Biology</i> , 2006, 10, 28-34.	2.8	77
14	Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 916-930.	6.6	102
16	Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 933-947.	2.0	7
17	The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 70-80.	2.0	26
18	Epigenetic regulation of immune escape genes in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1159-1184.	2.0	108
19	Treatment with HPMa copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 35-47.	2.0	57

#	ARTICLE	IF	CITATIONS
20	Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 381-389.	2.0	8
21	Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 449-468.	2.4	212
22	The Wild-Type Sequence (wt) p5325â€³5 Peptide Induces HLA-DR7 and HLA-DR11-Restricted CD4+ Th Cells Capable of Enhancing the Ex Vivo Expansion and Function of Anti-wt p53264â€³272 Peptide CD8+ T Cells. <i>Journal of Immunology</i> , 2006, 177, 6795-6803.	0.4	21
23	Accelerated Tumor Formation in a Fatless Mouse with Type 2 Diabetes and Inflammation. <i>Cancer Research</i> , 2006, 66, 5469-5476.	0.4	82
24	A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. <i>Expert Review of Dermatology</i> , 2006, 1, 805-823.	0.3	5
25	T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4254-4261.	0.8	68
26	T-cell receptor gene therapy for cancer: the progress to date and future objectives. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1207-1218.	1.4	20
27	Unmasking of Î±-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing Embolization. <i>Journal of Immunology</i> , 2007, 178, 1914-1922.	0.4	147
28	CD8+CD28â€³ T Regulatory Lymphocytes Inhibiting T Cell Proliferative and Cytotoxic Functions Infiltrate Human Cancers. <i>Journal of Immunology</i> , 2007, 179, 4323-4334.	0.4	207
29	An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer. <i>Acta OncolÃ³gica</i> , 2007, 46, 256-258.	0.8	4
30	Papillary thyroid carcinoma with lymph node metastases. <i>Growth Factors</i> , 2007, 25, 41-49.	0.5	15
31	Prostaglandin I2analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. <i>Journal of Leukocyte Biology</i> , 2007, 81, 809-817.	1.5	79
32	Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 7199-7206.	3.2	27
33	Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. <i>Oncology Reports</i> , 2007, 18, 745.	1.2	14
34	Protective autoimmunity in cancer (Review). <i>Oncology Reports</i> , 2007, 17, 245.	1.2	16
35	A Novel Approach to Generate Host Antitumor T Cells: Adoptive Immunotherapy by T cells Maturing in Xenogeneic thymus. <i>Journal of Immunotherapy</i> , 2007, 30, 83-88.	1.2	0
36	MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. <i>Vaccine</i> , 2007, 25, 1607-1618.	1.7	71
37	Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. <i>Journal of Pediatric Surgery</i> , 2007, 42, 54-61.	0.8	14

#	ARTICLE	IF	CITATIONS
38	CD40-induced countercurrent conduits for tumor escape or elimination?. Trends in Immunology, 2007, 28, 467-473.	2.9	28
39	Alopecia universalis associated with impaired interleukin-4 production and low serum IgE level. Journal of the American Academy of Dermatology, 2007, 57, S22-S25.	0.6	10
40	Engineered promiscuous T helper peptides for the induction of immune responses. Molecular Immunology, 2007, 44, 2205-2212.	1.0	2
41	Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Human Immunology, 2007, 68, 572-576.	1.2	18
42	Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Therapy, 2007, 14, 503-513.	2.3	38
43	Black Tea-Induced Decrease in IL-10 and TGF- $\beta$ 2 of Tumor Cells Promotes Th1/Tc1 Response in Tumor Bearer. Nutrition and Cancer, 2007, 58, 213-221.	0.9	6
44	Enhanced Antitumor Effects by the Coculture of Allotumor RNA-Pulsed Dendritic Cells with Autologous Cytokine-Induced Killer Cells on Hormone-Refractory Prostate Cancer. Cancer Investigation, 2007, 25, 527-534.	0.6	1
45	Receptor-Mediated Delivery of Antigens to Dendritic Cells: Anticancer Applications. Molecular Pharmaceutics, 2007, 4, 58-72.	2.3	30
46	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. Journal of Proteome Research, 2007, 6, 4025-4031.	1.8	88
47	Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning. Cytotherapy, 2007, 9, 771-784.	0.3	13
48	An epigenetic vaccine model active in the prevention and treatment of melanoma. Journal of Translational Medicine, 2007, 5, 64.	1.8	42
49	Possible stimulation of anti-tumor immunity using repeated cold stress: a hypothesis. Infectious Agents and Cancer, 2007, 2, 20.	1.2	22
50	Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. International Journal of Cancer, 2007, 121, 2031-2041.	2.3	45
51	Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominant cytokines and inhibits melanoma metastasis. Immunology Letters, 2007, 113, 19-28.	1.1	14
52	An Agonist Antibody Specific for CD40 Induces Dendritic Cell Maturation and Promotes Autologous Anti-tumour T-cell Responses in an In vitro Mixed Autologous Tumour Cell/Lymph Node Cell Model. Scandinavian Journal of Immunology, 2007, 65, 479-486.	1.3	37
53	Imbalances in circulating lymphocyte subsets in Hu antibody associated paraneoplastic neurological syndromes. European Journal of Neurology, 2007, 14, 1383-1391.	1.7	9
54	Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins. BMC Cancer, 2007, 7, 204.	1.1	19
55	Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. European Journal of Haematology, 2007, 79, 371-381.	1.1	11

#	ARTICLE	IF	CITATIONS
56	Immune suppression in renal cell carcinoma. <i>Seminars in Cancer Biology</i> , 2007, 17, 330-343.	4.3	35
57	Tumor immunoediting and immunosculpting pathways to cancer progression. <i>Seminars in Cancer Biology</i> , 2007, 17, 275-287.	4.3	167
58	li-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 601-613.	2.0	43
59	GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1653-1665.	2.0	38
60	Role of lymphocytes in the course of murine zymosan-induced peritonitis. <i>Inflammation Research</i> , 2008, 57, 272-278.	1.6	38
61	Potential contribution of naïve immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretion. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 359-366.	2.0	23
62	Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1745-1756.	2.0	20
63	Vitamin D receptor polymorphisms and the risk of cutaneous melanoma. <i>Cancer</i> , 2008, 113, 2398-2407.	2.0	66
64	Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity <i>in vitro</i> and <i>in vivo</i> . <i>European Journal of Immunology</i> , 2008, 38, 424-436.	1.6	139
65	TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. <i>Oncogene</i> , 2008, 27, 168-180.	2.6	154
66	Polarized immune responses differentially regulate cancer development. <i>Immunological Reviews</i> , 2008, 222, 145-154.	2.8	172
67	HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. <i>Oncogene</i> , 2008, 27, 5869-5885.	2.6	356
68	Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. <i>Nature Reviews Cancer</i> , 2008, 8, 351-360.	12.8	508
69	Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. <i>Tissue Antigens</i> , 2008, 72, 321-334.	1.0	72
70	Current State of Vaccine Therapies in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S28-S36.	1.1	23
71	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. <i>Blood</i> , 2008, 112, 4746-4754.	0.6	39
72	The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. <i>Vaccine</i> , 2008, 26, 4984-4990.	1.7	45
73	Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice. <i>Vaccine</i> , 2008, 26, 5928-5934.	1.7	17

#	ARTICLE	IF	CITATIONS
74	Hyperthermia on mesenchymal stem cells (MSCs) can sensitize tumor cells to undergo cell death. International Journal of Hyperthermia, 2008, 24, 638-648.	1.1	15
75	Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nature Clinical Practice Oncology, 2008, 5, 696-697.	4.3	10
76	Results of the First Phase I Clinical Trial of the Novel li-Key Hybrid Preventive HER-2/Peptide (AE37) Vaccine. Journal of Clinical Oncology, 2008, 26, 3426-3433.	0.8	127
77	Potent Tumor-Specific Protection Ignited by Adoptively Transferred CD4+ T Cells. Journal of Immunology, 2008, 181, 4363-4370.	0.4	22
78	Differential Regulatory Function of Resting and Preactivated Allergen-Specific CD4+CD25+ Regulatory T Cells in Th2-Type Airway Inflammation. Journal of Immunology, 2008, 181, 6889-6897.	0.4	40
79	Endosomal Proteases Influence the Repertoire of MAGE-A3 Epitopes Recognized In vivo by CD4+ T Cells. Cancer Research, 2008, 68, 1555-1562.	0.4	12
80	An HLA-DR Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2 Specific Immunity in Patients with Cancer. Cancer Research, 2008, 68, 4893-4901.	0.4	16
81	Effective cell transfer immunotherapy for lung cancer and its metastasis. Acta Oncologica, 2008, 47, 320-322.	0.8	0
82	Immunomodulating Activity of Agaricus brasiliensis KA21 in Mice and in Human Volunteers. Evidence-based Complementary and Alternative Medicine, 2008, 5, 205-219.	0.5	48
83	HLA class II antigen presentation by prostate cancer cells. Prostate Cancer and Prostatic Diseases, 2008, 11, 334-341.	2.0	31
84	Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature. Cancer Research, 2008, 68, 8066-8075.	0.4	91
85	Characterization of a Novel Nonclassical T Cell Clone with Broad Reactivity against Human Renal Cell Carcinomas. Journal of Immunology, 2008, 181, 3769-3776.	0.4	11
86	Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). International Journal of Oncology, 0, , .	1.4	97
87	Monitoring circulating tumor cells in cancer vaccine trials. Hum Vaccin, 2008, 4, 389-392.	2.4	8
88	Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 2008, 112, 362-373.	0.6	719
89	The TAG Family of Cancer/Testis Antigens is Widely Expressed in a Variety of Malignancies and Gives Rise to HLA-A2 Restricted Epitopes. Journal of Immunotherapy, 2008, 31, 7-17.	1.2	12
90	A Multipptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer. Journal of Immunotherapy, 2008, 31, 420-430.	1.2	100
91	Therapeutic vaccines for malignant brain tumors. Biologics: Targets and Therapy, 2008, 2, 753.	3.0	8

#	ARTICLE	IF	CITATIONS
92	Immunomodulation in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 734-740.	1.2	14
93	Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 517-526.	1.3	0
94	Selective addition of CXCR3+CCR4-CD4+ Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro. <i>Experimental and Molecular Medicine</i> , 2009, 41, 161.	3.2	23
95	Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1499-1510.	1.1	26
96	Cellular immunotherapy for ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 677-688.	1.4	28
97	Current immunotherapy for solid tumors. <i>Immunotherapy</i> , 2009, 1, 483-493.	1.0	8
98	Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease. <i>Carcinogenesis</i> , 2009, 30, 1064-1072.	1.3	45
99	Aberrant tumor-associated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay. <i>Journal of Immunological Methods</i> , 2009, 344, 116-120.	0.6	11
100	S.93. Characterization of Tumor-derived Exosomes and Their Role in Immunoregulation. <i>Clinical Immunology</i> , 2009, 131, S158.	1.4	0
101	Dendritic cells pulsed with GST-EGFR fusion protein: Effect in antitumor immunity against head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2010, 32, 626-635.	0.9	6
102	WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. <i>International Journal of Cancer</i> , 2009, 125, 381-387.	2.3	35
103	Dendritic-cell- and peptide-based vaccination strategies for glioma. <i>Neurosurgical Review</i> , 2009, 32, 265-273.	1.2	38
104	The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF- $\alpha$ mediated cellular immunity. <i>Biomaterials</i> , 2009, 30, 3934-3945.	5.7	177
105	Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 187-200.	2.0	72
106	CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1441-1448.	2.0	9
107	Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1609-1626.	2.0	44
108	A DNA adjuvant encoding a fusion protein between anti-CD3 single-chain Fv and AIMP1 enhances T helper type 1 cell-mediated immune responses in antigen-sensitized mice. <i>Immunology</i> , 2009, 126, 84-91.	2.0	4
109	Serum autoantibodies as biomarkers for early cancer detection. <i>FEBS Journal</i> , 2009, 276, 6880-6904.	2.2	272

#	ARTICLE	IF	CITATIONS
110	Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias. <i>Clinical Biochemistry</i> , 2009, 42, 1144-1157.	0.8	29
111	Adoptive immunotherapy of cancer using CD4+ T cells. <i>Current Opinion in Immunology</i> , 2009, 21, 200-208.	2.4	202
112	Cancer vaccination with telomerase peptide GV1001. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 687-694.	1.9	70
113	Antigen Delivery with Poly(Propylacrylic Acid) Conjugation Enhances MHC-1 Presentation and T-Cell Activation. <i>Bioconjugate Chemistry</i> , 2009, 20, 241-248.	1.8	77
114	Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3. <i>Vaccine</i> , 2009, 27, 4718-4723.	1.7	3
115	li-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers. <i>Vaccine</i> , 2009, 27, 4641-4647.	1.7	4
116	CD4 <sup>+</sup> T cells in antitumor immunity: utility of an li-Key HER2/neu hybrid peptide vaccine (AE37). <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 71-78.	1.4	22
117	Chronic restraint stress impairs T-cell immunity and promotes tumor progression in mice. <i>Stress</i> , 2009, 12, 134-143.	0.8	64
118	EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. <i>Blood</i> , 2009, 113, 3494-3502.	0.6	68
119	Tumor Secretion of VEGF Induces Endothelial Cells to Suppress T cell Functions Through the Production of PGE2. <i>Journal of Immunotherapy</i> , 2010, 33, 126-135.	1.2	56
120	Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. <i>Blood</i> , 2010, 116, 171-179.	0.6	136
121	Capturing and Characterizing Immune Cells from Breast Tumor Microenvironment: An Innovative Surgical Approach. <i>Annals of Surgical Oncology</i> , 2010, 17, 2677-2684.	0.7	16
122	Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 161-171.	2.0	12
123	DNA vaccination strategies for anti-tumour effective gene therapy protocols. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1583-1591.	2.0	40
124	Alternative li-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1825-1838.	2.0	16
125	Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1861-1868.	1.2	2
126	The CD4 <sup>+</sup> T cell epitope binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides. <i>European Journal of Immunology</i> , 2010, 40, 1603-1616.	1.6	6
127	Mouse models for melanoma: a personal perspective. <i>Experimental Dermatology</i> , 2010, 19, 157-164.	1.4	71

#	ARTICLE	IF	CITATIONS
128	Organ microenvironment plays significant roles through Fas ligand in vaccine-induced CD4 <sup>+</sup> T cell dependent suppression of tumor growth at the orthotopic site. <i>Cancer Science</i> , 2010, 101, 1965-1969.	1.7	1
129	Production of Cytokines During Interaction of Peripheral Blood Mononuclear Cells with Autologous Ovarian Cancer Cells or Benign Ovarian Tumour Cells. <i>Scandinavian Journal of Immunology</i> , 2010, 71, 91-98.	1.3	31
130	The polarization of immune cells in the tumour environment by TGF $\beta$ <sup>2</sup> . <i>Nature Reviews Immunology</i> , 2010, 10, 554-567.	10.6	795
131	Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract. <i>Pharmaceuticals</i> , 2010, 3, 2495-2516.	1.7	8
132	Combined influence of adjuvant therapy and interval after surgery on peripheral CD4 <sup>+</sup> T lymphocytes in patients with esophageal squamous cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 113-120.	0.8	2
133	CD4 <sup>+</sup> CD25 <sup>+</sup> Foxp3 <sup>+</sup> Regulatory T Cells Depletion May Attenuate the Development of Silica-Induced Lung Fibrosis in Mice. <i>PLoS ONE</i> , 2010, 5, e15404.	1.1	115
134	Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. <i>Immunotherapy</i> , 2010, 2, 85-97.	1.0	20
135	Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. <i>Carcinogenesis</i> , 2010, 31, 834-841.	1.3	44
136	Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. <i>Expert Review of Vaccines</i> , 2010, 9, 1007-1016.	2.0	33
137	A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102. <i>Clinical Cancer Research</i> , 2010, 16, 825-834.	3.2	15
138	Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. <i>Journal of Clinical Oncology</i> , 2010, 28, 4390-4399.	0.8	285
139	Vaccine-induced antibody responses in patients with carcinoma. <i>Expert Review of Vaccines</i> , 2010, 9, 579-594.	2.0	6
140	Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-19.	3.0	17
141	Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-15.	3.0	23
142	Antibodies in cancer immunotherapy. <i>Cancer Biomarkers</i> , 2010, 6, 291-305.	0.8	2
143	A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4 <sup>+</sup> T cells restricted by prevalent HLA-DR alleles. <i>International Immunology</i> , 2010, 22, 863-873.	1.8	39
144	The Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 2024-2036.	0.5	243
145	Impact of stress on cancer metastasis. <i>Future Oncology</i> , 2010, 6, 1863-1881.	1.1	350

#	ARTICLE	IF	CITATIONS
146	Impact of $\hat{I}^3$ -chain cytokines on EBV-specific T cell cultures. <i>Journal of Translational Medicine</i> , 2010, 8, 121.	1.8	4
147	STAT3 Silencing in Dendritic Cells by siRNA Polyplexes Encapsulated in PLGA Nanoparticles for the Modulation of Anticancer Immune Response. <i>Molecular Pharmaceutics</i> , 2010, 7, 1643-1654.	2.3	86
148	In vitro immunogenic and immunostimulatory effects of zwitterionized 23-valent pneumococcal polysaccharide vaccine compared with nonzwitterionized vaccine. <i>Current Therapeutic Research</i> , 2010, 71, 60-77.	0.5	6
149	Whole protein and defined CD8 <sup>+</sup> and CD4 <sup>+</sup> peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. <i>Immunology and Cell Biology</i> , 2011, 89, 904-913.	1.0	22
150	Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy. <i>Immunotherapy</i> , 2011, 3, 407-421.	1.0	41
151	Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial. <i>Clinical Cancer Research</i> , 2011, 17, 6847-6857.	3.2	149
153	IL-4 and TNF- $\hat{I}$ Polymorphisms Are Associated with Risk of Multiple Superficial Tumors or Carcinoma in situ Development. <i>Urologia Internationalis</i> , 2011, 87, 457-463.	0.6	7
154	Colorectal cancer vaccines in clinical trials. <i>Expert Review of Vaccines</i> , 2011, 10, 899-921.	2.0	23
155	Effect of N-methyl-D-aspartate receptor antagonist on T helper cell differentiation induced by phorbol-myristate-acetate and ionomycin. <i>Cytokine</i> , 2011, 56, 458-465.	1.4	30
156	Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. <i>Expert Review of Vaccines</i> , 2011, 10, 755-774.	2.0	14
157	Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model. <i>Vaccine</i> , 2011, 29, 5904-5910.	1.7	12
158	Induction of Cellular Immune Responses in Patients With Stage-I Multiple Myeloma After Vaccination With Autologous Idiotype-pulsed Dendritic Cells. <i>Journal of Immunotherapy</i> , 2011, 34, 100-106.	1.2	47
159	Colorectal Cancer- $\hat{I}$ Derived Foxp3 <sup>+</sup> IL-17 <sup>+</sup> T Cells Suppress Tumour-Specific CD8 <sup>+</sup> T Cells. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 47-51.	1.3	44
160	Identification of promiscuous HLA-DR-restricted CD4 <sup>+</sup> T cell epitopes on the cancer-testis antigen HCA587. <i>Cancer Science</i> , 2011, 102, 1455-1461.	1.7	14
161	Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8 <sup>+</sup> T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice. <i>Cancer Gene Therapy</i> , 2011, 18, 489-499.	2.2	13
162	T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor. <i>BMC Cancer</i> , 2011, 11, 225.	1.1	14
163	Oral administration of fluoxetine alters the proliferation/apoptosis balance of lymphoma cells and up-regulates T cell immunity in tumor-bearing mice. <i>European Journal of Pharmacology</i> , 2011, 659, 265-272.	1.7	24
164	Improving cancer immunotherapy by targeting tumor-induced immune suppression. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 125-140.	2.7	127

#	ARTICLE	IF	CITATIONS
165	Depletion of CD4+CD25+Foxp3+ regulatory T cells with anti-CD25 antibody may exacerbate the 1,3- $\beta$ -glucan-induced lung inflammatory response in mice. <i>Archives of Toxicology</i> , 2011, 85, 1383-1394.	1.9	15
166	Tetraspanins in the immune response against cancer. <i>Immunology Letters</i> , 2011, 138, 129-136.	1.1	37
167	Melatonin, Immune Function and Cancer. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2011, 5, 109-123.	0.7	88
168	Absence of Class II $\beta$ -Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells. <i>Cancer Research</i> , 2011, 71, 2507-2517.	0.4	21
169	Induction of HLA-DP4 $\beta$ -Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell. <i>Clinical Cancer Research</i> , 2011, 17, 5392-5401.	3.2	24
170	Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 4568-4580.	3.2	105
171	Glycan mediated immune responses to tumor cells. <i>Hum Vaccin</i> , 2011, 7, 156-165.	2.4	14
172	MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells. <i>Journal of Immunology</i> , 2011, 187, 316-324.	0.4	15
173	Forced Expression of HLA-DM at the Surface of Dendritic Cells Increases Loading of Synthetic Peptides on MHC Class II Molecules and Modulates T Cell Responses. <i>Journal of Immunology</i> , 2011, 187, 74-81.	0.4	11
174	Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. <i>Cancer Biology and Therapy</i> , 2011, 11, 581-583.	1.5	2
175	Induction of Immune Tolerance in Asthmatic Mice by Vaccination with DNA Encoding an Allergen $\beta$ -Cytotoxic T Lymphocyte-Associated Antigen 4 Combination. <i>Vaccine Journal</i> , 2011, 18, 807-814.	3.2	11
176	Enhanced T Cell Immunity by B7-H4 Downregulation in Nonsmall-Cell Lung Cancer Cell Lines. <i>Journal of International Medical Research</i> , 2012, 40, 497-506.	0.4	10
177	Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders. <i>Clinical Cancer Research</i> , 2012, 18, 4850-4860.	3.2	66
178	Anesthesia in patients with cancer disorders. <i>Current Opinion in Anaesthesiology</i> , 2012, 25, 376-384.	0.9	73
179	Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2012, 12, 289-302.	0.5	1
180	L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice. <i>Clinical Cancer Research</i> , 2012, 18, 2861-2871.	3.2	15
181	Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1931-1937.	0.4	77
182	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. <i>Clinical Cancer Research</i> , 2012, 18, 6284-6295.	3.2	54

#	ARTICLE	IF	CITATIONS
183	The split nature of tumor-infiltrating leukocytes. <i>Oncolimmunology</i> , 2012, 1, 717-725.	2.1	131
184	The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2012, 12, 279-288.	0.5	2
185	Inhibition of neuroblastoma cell growth by TREG1-mutated human lymphocytes. <i>Oncology Reports</i> , 2012, 27, 1689-94.	1.2	13
186	Dendritic cell-based vaccines: barriers and opportunities. <i>Future Oncology</i> , 2012, 8, 1273-1299.	1.1	110
187	Immunotherapy with dendritic cells in an animal model of early pulmonary metastatic squamous cell carcinoma. <i>Laryngoscope</i> , 2012, 122, 2442-2446.	1.1	5
188	Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. <i>Immunology Letters</i> , 2012, 148, 126-132.	1.1	34
189	Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients. <i>Molecular Therapy</i> , 2012, 20, 1063-1074.	3.7	85
190	C6-ceramide enhances Interleukin-12-mediated T helper type 1 cell responses through a cyclooxygenase-2-dependent pathway. <i>Immunobiology</i> , 2012, 217, 601-609.	0.8	13
192	Dendritic Cell Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 187-200.	0.8	13
193	Antitumor effect of new multiple antigen peptide based on HLA-A*0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT). <i>Cancer Science</i> , 2012, 103, 1920-1928.	1.7	14
194	Peptide Vaccine. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 166-177.	0.8	8
195	Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. <i>Pharmacological Research</i> , 2012, 66, 7-18.	3.1	61
196	Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies. <i>BioDrugs</i> , 2012, 26, 83-99.	2.2	33
198	Adoptive Transfer of Mammaglobin-A Epitope Specific CD8 T Cells Combined with a Single Low Dose of Total Body Irradiation Eradicates Breast Tumors. <i>PLoS ONE</i> , 2012, 7, e41240.	1.1	8
199	Induction of HCA587-Specific Antitumor Immunity with HCA587 Protein Formulated with CpG and ISCOM in Mice. <i>PLoS ONE</i> , 2012, 7, e47219.	1.1	15
200	Post-Transcriptional and Epigenetic Regulation of Antigen Processing Machinery (APM) Components and HLA-I in Cervical Cancers from Uighur Women. <i>PLoS ONE</i> , 2012, 7, e44952.	1.1	49
201	A Comparison of HLA Genotype with Inflammation in Uveal Melanoma. , 2012, 53, 2640.		7
202	Imageable Antigen-Presenting Gold Nanoparticle Vaccines for Effective Cancer Immunotherapy In Vivo. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 8800-8805.	7.2	163

#	ARTICLE	IF	CITATIONS
203	Morphine, but Not Ketamine, Decreases the Ratio of Th1/Th2 in CD4-positive Cells Through T-bet and GATA3. <i>Inflammation</i> , 2012, 35, 1069-1077.	1.7	26
205	The clinical implications of antitumor immunity in head and neck cancer. <i>Laryngoscope</i> , 2012, 122, 144-157.	1.1	52
206	LMP gene promoter hypermethylation is a mechanism for its down regulation in Kazaká€™s esophageal squamous cell carcinomas. <i>Molecular Biology Reports</i> , 2013, 40, 2069-2075.	1.0	10
207	Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 911-925.	1.4	16
208	Tumor-Associated Glycans and Immune Surveillance. <i>Vaccines</i> , 2013, 1, 174-203.	2.1	41
209	The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 761-772.	2.0	22
210	The role of gamma interferon in DNA vaccine-induced tumor immunity targeting simian virus 40 large tumor antigen. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 371-382.	2.0	0
211	Enhanced anti-cancer activity of human dendritic cells sensitized with gamma-irradiation-induced apoptotic colon cancer cells. <i>Cancer Letters</i> , 2013, 335, 278-288.	3.2	16
212	A cancer vaccine based on the marine antimicrobial peptide pardaxin (GE33) for control of bladder-associated tumors. <i>Biomaterials</i> , 2013, 34, 10151-10159.	5.7	25
213	Loading of dendritic cells for immunotherapy. <i>ISBT Science Series</i> , 2013, 8, 161-164.	1.1	1
214	Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. <i>International Journal of Clinical Oncology</i> , 2013, 18, 657-665.	1.0	25
215	Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemiaâ€™ Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 5079-5091.	3.2	81
216	Prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 253-262.	2.0	12
217	Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 861-870.	1.2	10
218	Immunotherapy for head and neck cancer patients: shifting the balance. <i>Immunotherapy</i> , 2013, 5, 49-61.	1.0	20
219	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. <i>Annals of Oncology</i> , 2013, 24, 1740-1748.	0.6	74
220	AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1599-1608.	2.0	29
221	Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies. <i>Immunotherapy</i> , 2013, 5, 1243-1254.	1.0	4

#	ARTICLE	IF	CITATIONS
222	Intracerebral Administration of Heat-Inactivated <i>Staphylococcus Epidermidis</i> Enhances Oncolysis and Prolongs Survival in a 9L Orthotopic Gliosarcoma Model. <i>Cellular Physiology and Biochemistry</i> , 2013, 31, 614-624.	1.1	6
223	Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1073-1077.	1.4	20
224	Schedule-dependent therapeutic efficacy of L19m TNF $\alpha$ and melphalan combined with gemcitabine. <i>Cancer Medicine</i> , 2013, 2, 478-487.	1.3	13
225	HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. <i>Onc Immunology</i> , 2013, 2, e24962.	2.1	22
226	Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. <i>Onc Immunology</i> , 2013, 2, e24440.	2.1	11
227	STAT3 activation. <i>Jak-stat</i> , 2013, 2, e23010.	2.2	159
228	Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice. <i>Oncology Letters</i> , 2013, 6, 748-752.	0.8	7
229	Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-6.	3.3	5
230	Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2014, 05, .	1.5	3
231	Oncofetal antigen/immature laminin receptor protein in pregnancy and cancer. <i>Cellular and Molecular Biology Letters</i> , 2014, 19, 393-406.	2.7	9
232	Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	1.4	100
233	Clinical Application of Plasmid-Based Cancer Vaccines. , 2014, , 335-343.		0
234	CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. <i>Journal of Biophotonics</i> , 2014, 7, 897-905.	1.1	50
235	pDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T cell responses. <i>European Journal of Immunology</i> , 2014, 44, 2880-2892.	1.6	16
236	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. <i>Advanced Drug Delivery Reviews</i> , 2014, 79-80, 222-237.	6.6	146
237	Melatonin and Immune Function: Clinical Significance. , 2014, , 143-157.		2
238	Local hyperthermia treatment of tumors induces CD8+ T cell-mediated resistance against distal and secondary tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1273-1285.	1.7	156
239	Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4+ T cells in vitro. <i>International Immunopharmacology</i> , 2014, 20, 307-315.	1.7	27

#	ARTICLE	IF	CITATIONS
240	Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2910-2921.	3.2	24
241	Interaction of Immune and Cancer Cells. , 2014, , .		0
242	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. , 2014, 142, 339-350.		92
243	Niche Inheritance: A Cooperative Pathway to Enhance Cancer Cell Fitness Through Ecosystem Engineering. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 1478-1485.	1.2	45
244	Tumor-specific CD4 <sup>+</sup> T cells maintain effector and memory tumor-specific CD8 <sup>+</sup> T cells. <i>European Journal of Immunology</i> , 2014, 44, 69-79.	1.6	98
245	TGF $\beta$ in T cell biology and tumor immunity: Angel or devil?. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 423-435.	3.2	81
246	Stromal Fibroblasts and the Immune Microenvironment: Partners in Mammary Gland Biology and Pathology?. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2014, 19, 169-182.	1.0	31
248	Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. <i>BMC Cancer</i> , 2014, 14, 251.	1.1	51
249	Microglia in Health and Disease. , 2014, , .		19
250	The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. <i>Biomaterials</i> , 2014, 35, 5491-5504.	5.7	108
251	Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-poly(lactide). <i>Biomaterials</i> , 2014, 35, 1686-1695.	5.7	27
252	Epithelial ovarian cancer stem-like cells expressing $\beta$ -gal epitopes increase the immunogenicity of tumor associated antigens. <i>BMC Cancer</i> , 2015, 15, 956.	1.1	8
253	The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. <i>OncoTargets and Therapy</i> , 2015, 8, 761.	1.0	16
254	Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2015, 06, .	1.5	7
255	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015, 7, 2397-2414.	1.7	61
256	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. <i>Vaccines</i> , 2015, 3, 490-502.	2.1	43
257	Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice. <i>Marine Drugs</i> , 2015, 13, 3241-3258.	2.2	13
258	A top-down view of the tumor microenvironment: structure, cells and signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 33.	1.8	70

#	ARTICLE	IF	CITATIONS
259	Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	29
260	<i>In vitro</i> Toxicity and <i>In vivo</i> Immunomodulatory Effects of Flavokawain A and Flavokawain B in Balb/C Mice. <i>Natural Product Communications</i> , 2015, 10, 1934578X1501000.	0.2	11
261	CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer. <i>Oncotarget</i> , 2015, 6, 33486-33499.	0.8	108
262	A Gender Factor in Shaping T-Cell Immunity to Melanoma. <i>Frontiers in Oncology</i> , 2015, 5, 8.	1.3	13
263	Circadian rhythms and new options for novel anticancer therapies. <i>ChronoPhysiology and Therapy</i> , 0, 1.	0.5	2
264	Tumor Antigen and Epitope Identification for Preclinical and Clinical Evaluation. , 2015, , 55-71.		0
265	Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 549-554.	1.0	26
267	Fish Oil Enhances T Cell Function and Tumor Infiltration and Is Correlated With a Cancer Prevention Effect in HER-2/neu But Not PyMT Transgenic Mice. <i>Nutrition and Cancer</i> , 2015, 67, 965-975.	0.9	8
268	Hematological Effects, Serum, and Pulmonary Cytokine Profiles in a Melanoma Mouse Model Treated with GK1. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 247-254.	0.7	5
269	The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors. <i>Journal of Immunology</i> , 2015, 195, 1891-1901.	0.4	14
270	Liposome-Encapsulated CpG Enhances Antitumor Activity Accompanying the Changing of Lymphocyte Populations in Tumor via Intratumoral Administration. <i>Nucleic Acid Therapeutics</i> , 2015, 25, 95-102.	2.0	15
271	Design and Antigenic Epitopes Prediction of a New Trial Recombinant Multiepitopic Rotaviral Vaccine: <i>In Silico</i> Analyses. <i>Viral Immunology</i> , 2015, 28, 325-330.	0.6	11
272	Pulmonary Alveolar Macrophages Contribute to the Premetastatic Niche by Suppressing Antitumor T Cell Responses in the Lungs. <i>Journal of Immunology</i> , 2015, 194, 5529-5538.	0.4	131
273	Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. <i>Molecular Therapy</i> , 2015, 23, 387-395.	3.7	46
274	Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. <i>Journal of Immunology</i> , 2015, 195, 4537-4544.	0.4	12
275	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1609-1621.	2.0	42
276	Dichotomous role of protein kinase A type I (PKAI) in the tumor microenvironment: A potential target for <i>two-in-one</i> ™ cancer chemoimmunotherapeutics. <i>Cancer Letters</i> , 2015, 369, 9-19.	3.2	13
277	Immunomodulatory effects of <i>Lactobacillus</i> strains: emphasis on their effects on cancer cells. <i>Immunotherapy</i> , 2015, 7, 1307-1329.	1.0	48

#	ARTICLE	IF	CITATIONS
278	Melatonin: a "Higgs boson" in human reproduction. <i>Gynecological Endocrinology</i> , 2015, 31, 92-101.	0.7	33
279	Th9 Cells as Targets for Immunotherapy. , 2016, , 165-184.		0
280	Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy. <i>Cancers</i> , 2016, 8, 86.	1.7	6
281	Boosting Tumor-Specific Immunity Using PDT. <i>Cancers</i> , 2016, 8, 91.	1.7	74
282	Potential Anticancer Drugs Targeting Immune Pathways. , 0, , .		0
283	T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy. <i>Oncolmunology</i> , 2016, 5, e1249090.	2.1	16
284	Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. <i>Annals of Oncology</i> , 2016, 27, 1241-1248.	0.6	77
285	Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. <i>Oncolmunology</i> , 2016, 5, e1227902.	2.1	26
286	STAT Inhibitors in Cancer. <i>Cancer Drug Discovery and Development</i> , 2016, , .	0.2	1
287	The Pathophysiologic Role of Disrupted Circadian and Neuroendocrine Rhythms in Breast Carcinogenesis. <i>Endocrine Reviews</i> , 2016, 37, 450-466.	8.9	37
288	Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1213-1222.	2.0	11
289	Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol. <i>Scientific Reports</i> , 2016, 6, 18423.	1.6	62
290	Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model. <i>Radiology</i> , 2016, 280, 413-424.	3.6	98
291	STAT Proteins in Cancer. <i>Cancer Drug Discovery and Development</i> , 2016, , 33-47.	0.2	1
292	Obesity-associated cancer: an immunological perspective. <i>Proceedings of the Nutrition Society</i> , 2016, 75, 125-138.	0.4	30
293	Polymorphisms of HLA-DQB1 predict survival of hepatitis B virus-related hepatocellular carcinoma patients receiving hepatic resection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 739-747.	0.7	12
294	Morphine Suppresses T helper Lymphocyte Differentiation to Th1 Type Through PI3K/AKT Pathway. <i>Inflammation</i> , 2016, 39, 813-821.	1.7	11
295	Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors. <i>Frontiers in Nanobiomedical Research</i> , 2016, , 309-347.	0.1	3

#	ARTICLE	IF	CITATIONS
296	Conditioning of naive CD4+ T cells for enhanced peripheral Foxp3 induction by nonspecific bystander inflammation. <i>Nature Immunology</i> , 2016, 17, 297-303.	7.0	20
297	Generation and Expansion of T Helper 17 Lymphocytes Ex Vivo. <i>Methods in Molecular Biology</i> , 2016, 1371, 101-113.	0.4	0
298	Why Target Immune Cells for Plasma Treatment of Cancer. <i>Plasma Chemistry and Plasma Processing</i> , 2016, 36, 259-268.	1.1	102
300	Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 161-166.	0.6	21
301	Fuzheng Qingjie Granules Inhibit Growth of Hepatoma Cells via Inducing Mitochondria-Mediated Apoptosis and Enhancing Immune Function. <i>Integrative Cancer Therapies</i> , 2017, 16, 329-338.	0.8	16
302	The Role of the JAK/STAT Signalling Pathway in Immunoregulation of Gastrointestinal Cancers. , 2017, , 147-186.		1
303	Modelling and investigation of the $CD^{4+}$ cells "Macrophages paradox in melanoma immunotherapies. <i>Journal of Theoretical Biology</i> , 2017, 420, 82-104.	0.8	17
304	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 479-488.	1.1	14
305	Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system. <i>Human Immunology</i> , 2017, 78, 327-335.	1.2	36
306	Human Tumor Antigens Yesterday, Today, and Tomorrow. <i>Cancer Immunology Research</i> , 2017, 5, 347-354.	1.6	94
307	Thermal ablation and immunomodulation: From preclinical experiments to clinical trials. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 651-659.	1.8	74
308	A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 851-863.	2.0	19
309	Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 49-56.	0.7	3
311	The Function and Diagnostic Potential of Adipocyte-Derived Factors in the Tumor Microenvironment. , 2017, , 129-166.		0
312	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 6119-6130.	0.4	92
313	The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. <i>Human Pathology</i> , 2017, 69, 110-117.	1.1	81
314	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 527-537.	3.3	59
315	Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response. <i>Small</i> , 2017, 13, 1701741.	5.2	55

#	ARTICLE	IF	CITATIONS
316	CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2871-2880.	1.9	29
317	Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity. <i>International Journal of Cancer</i> , 2017, 141, 2505-2516.	2.3	23
318	An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. <i>Mathematical Biosciences</i> , 2017, 292, 1-9.	0.9	44
319	Characterisation of the cancer-associated glucocorticoid system: key role of 11 $\beta$ -hydroxysteroid dehydrogenase type 2. <i>British Journal of Cancer</i> , 2017, 117, 984-993.	2.9	30
320	Derp1-modified dendritic cells attenuate allergic inflammation by regulating the development of T helper type1(Th1)/Th2 cells and regulatory T cells in a murine model of allergic rhinitis. <i>Molecular Immunology</i> , 2017, 90, 172-181.	1.0	37
321	Evolving Insights for MHC Class II Antigen Processing and Presentation in Health and Disease. <i>Current Pharmacology Reports</i> , 2017, 3, 213-220.	1.5	8
322	Effects of epidermal growth factor receptor fusion protein on the cytotoxic activity of SOCS1-silenced dendritic cells in vitro. <i>Oncology Reports</i> , 2018, 39, 1306-1312.	1.2	1
323	Progress in Vaccine Therapies for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 315-330.	0.8	11
324	Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	4
325	Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model. <i>Oncology Research</i> , 2017, 25, 1579-1587.	0.6	45
326	Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. <i>Oncotarget</i> , 2017, 8, 71249-71284.	0.8	138
327	CD47, a multi-faceted target for cancer immunotherapy. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2017, , .	0.1	1
328	Size/Charge Changeable Acidity-Responsive Micelleplex for Photodynamic-Improved PD-L1 Immunotherapy with Enhanced Tumor Penetration. <i>Advanced Functional Materials</i> , 2018, 28, 1707249.	7.8	147
329	Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model. <i>Cancer Science</i> , 2018, 109, 956-965.	1.7	26
330	Androgen receptor moonlighting in the prostate cancer microenvironment. <i>Endocrine-Related Cancer</i> , 2018, 25, R331-R349.	1.6	18
331	Low-molecular-weight polysaccharides from <i>Agaricus blazei</i> Murrill modulate the Th1 response in cancer immunity. <i>Oncology Letters</i> , 2018, 15, 3429-3436.	0.8	15
332	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. <i>Breast Cancer Research</i> , 2018, 20, 15.	2.2	71
333	Influence of Physicochemical Properties of Lipopeptide Adjuvants on the Immune Response: A Rationale for Engineering a Potent Vaccine. <i>Chemistry - A European Journal</i> , 2018, 24, 9892-9902.	1.7	9

#	ARTICLE	IF	CITATIONS
334	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	2.4	351
335	Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 558-567.	1.6	15
336	Recombinant protein rMBP-NAP restricts tumor progression by triggering antitumor immunity in mouse metastatic lung cancer. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 113-119.	0.7	4
337	The role of STAT3 in leading the crosstalk between human cancers and the immune system. <i>Cancer Letters</i> , 2018, 415, 117-128.	3.2	237
338	Role of extracellular vesicles in glioma progression. <i>Molecular Aspects of Medicine</i> , 2018, 60, 38-51.	2.7	63
339	Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. <i>ChemBioChem</i> , 2018, 19, 121-125.	1.3	14
340	Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. <i>Journal of Controlled Release</i> , 2018, 269, 364-373.	4.8	52
342	Immunological effects of photodynamic therapy in the treatment of actinic keratosis and squamous cell carcinoma. <i>Photodiagnosis and Photodynamic Therapy</i> , 2018, 24, 342-348.	1.3	20
343	Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3311.	1.8	14
344	Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma. <i>NeuroMolecular Medicine</i> , 2018, 20, 452-474.	1.8	18
345	Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope. <i>Molecules</i> , 2018, 23, 2233.	1.7	15
347	Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine. <i>Clinical Cancer Research</i> , 2018, 24, 5335-5346.	3.2	78
348	Antitumor efficacy of the Runx2 dendritic cell vaccine in triple-negative breast cancer in <i>in vitro</i> . <i>Oncology Letters</i> , 2018, 16, 2813-2822.	0.8	9
349	Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 136.	1.3	50
350	The Emerging Role of Gas Plasma in Oncotherapy. <i>Trends in Biotechnology</i> , 2018, 36, 1183-1198.	4.9	89
351	Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878527.	0.8	19
352	A novel dendritic cell-based direct ex vivo assay for detection and enumeration of circulating antigen-specific human T cells. <i>Cytotechnology</i> , 2018, 70, 1325-1335.	0.7	3
353	Anti-leukemic activity of a four-plant mixture in a leukemic rat model. <i>Journal of Basic and Applied Zoology</i> , 2018, 79, .	0.4	15

#	ARTICLE	IF	CITATIONS
354	Subchronic toxicity, immunoregulation and anti-breast tumor effect of Nordamnacantal, an anthraquinone extracted from the stems of <i>Morinda citrifolia</i> L. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 31.	3.7	28
355	IFN $\gamma$ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy. <i>Cancer Research</i> , 2018, 78, 5706-5717.	0.4	79
356	Complex interplay between tumor microenvironment and cancer therapy. <i>Frontiers of Medicine</i> , 2018, 12, 426-439.	1.5	37
357	Tailoring inorganic nanoadjuvants towards next-generation vaccines. <i>Chemical Society Reviews</i> , 2018, 47, 4954-4980.	18.7	95
358	Chemokines in breast cancer: Regulating metabolism. <i>Cytokine</i> , 2018, 109, 57-64.	1.4	21
359	Enhanced anti-tumor immunotherapy by dissolving microneedle patch loaded ovalbumin. <i>PLoS ONE</i> , 2019, 14, e0220382.	1.1	17
360	ReaxFF-based molecular dynamics simulation of DNA molecules destruction in cancer cells by plasma ROS. <i>Physics of Plasmas</i> , 2019, 26, 083504.	0.7	7
361	pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks. <i>Frontiers in Genetics</i> , 2019, 10, 858.	1.1	247
362	Examining Peripheral and Tumor Cellular Immune in Patients With Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1767.	2.2	44
363	Mesoporous Silica Nanoparticles Doped with Gold Nanoparticles for Combined Cancer Immunotherapy and Photothermal Therapy. <i>ACS Applied Bio Materials</i> , 2019, 2, 3630-3638.	2.3	37
364	Effective Radiotherapy in Tumor Assisted by <i>Ganoderma lucidum</i> Polysaccharide-Conjugated Bismuth Sulfide Nanoparticles through Radiosensitization and Dendritic Cell Activation. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 27536-27547.	4.0	62
365	DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen. <i>Acta Biomaterialia</i> , 2019, 96, 480-490.	4.1	64
366	Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 26637-26647.	4.0	13
367	Dual oxidase 1 and NADPH oxidase 2 exert favorable effects in cervical cancer patients by activating immune response. <i>BMC Cancer</i> , 2019, 19, 1078.	1.1	16
368	Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2019, 570, 118636.	2.6	24
369	STAT3, a Master Regulator of Anti-Tumor Immune Response. <i>Cancers</i> , 2019, 11, 1280.	1.7	68
370	Anti-Tumor Potential of a 5-HT $_3$ Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation. <i>Journal of Clinical Medicine</i> , 2019, 8, 1380.	1.0	6
371	The Immune Microenvironment of Breast Cancer Progression. <i>Cancers</i> , 2019, 11, 1375.	1.7	68

#	ARTICLE	IF	CITATIONS
372	Understanding the Anti-Tumor Properties Mediated by the Synthetic Peptide GK-1. , 2019, , .		0
373	Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination. <i>Oncolmmunology</i> , 2019, 8, e1565236.	2.1	7
374	The prognostic value of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2019, 17, 85.	0.8	60
375	Novel TCR-based biologics: mobilising T cells to warm "cold"™ tumours. <i>Cancer Treatment Reviews</i> , 2019, 77, 35-43.	3.4	57
376	Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition " implications for the next generation of DC vaccines. <i>Oncolmmunology</i> , 2019, 8, e1593803.	2.1	24
377	Novel biomanufacturing platform for large-scale and high-quality human T cells production. <i>Journal of Biological Engineering</i> , 2019, 13, 34.	2.0	11
378	Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches. <i>Biosensors and Bioelectronics</i> , 2019, 139, 111315.	5.3	53
379	Tumor mechanisms of resistance to immune attack. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 61-100.	0.9	9
380	MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. <i>Journal of Controlled Release</i> , 2019, 303, 223-236.	4.8	58
381	Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-11.	0.5	8
382	Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 126-151.	4.6	128
383	Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer. <i>Molecular Therapy</i> , 2019, 27, 507-517.	3.7	67
384	Si-doping increases the adjuvant activity of hydroxyapatite nanorods. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 174, 300-307.	2.5	16
385	Lipoxidation and cancer immunity. <i>Redox Biology</i> , 2019, 23, 101103.	3.9	17
386	Optimizing immune cell therapies with artificial intelligence. <i>Journal of Theoretical Biology</i> , 2019, 461, 34-40.	0.8	12
387	T lymphocyte subsets in cancer immunity: Friends or foes. <i>Journal of Leukocyte Biology</i> , 2019, 105, 243-255.	1.5	110
388	Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. <i>Journal of Immunology</i> , 2019, 202, 278-291.	0.4	61
389	Immunoregulation effects of TIM-3 on tumors. <i>Neoplasma</i> , 2019, 66, 167-175.	0.7	11

#	ARTICLE	IF	CITATIONS
390	Effects of dasatinib on CD8+T, Th1, and Treg cells in patients with chronic myeloid leukemia. <i>Journal of International Medical Research</i> , 2020, 48, 030006051987732.	0.4	6
391	Virus-like particles for vaccination against cancer. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1579.	3.3	74
392	The evolution of resistance and tolerance as cancer defences. <i>Parasitology</i> , 2020, 147, 255-262.	0.7	10
393	Mobile DNA tetrahedron on ultra-low adsorption lipid membrane for directional control of cell sensing. <i>Sensors and Actuators B: Chemical</i> , 2020, 307, 127570.	4.0	9
394	Reactive-ester derived polymer nanogels for cancer immunotherapy. <i>European Polymer Journal</i> , 2020, 124, 109481.	2.6	16
395	Platinum Derivatives Effects on Anticancer Immune Response. <i>Biomolecules</i> , 2020, 10, 13.	1.8	55
396	Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone. <i>Journal of Controlled Release</i> , 2020, 328, 617-630.	4.8	112
397	<p>&lt;p>Application and Prospects of Molecular Imaging in Immunotherapy&lt;/p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9389-9403.	0.9	8
398	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	5.8	46
399	Sex and Gender Disparities in Melanoma. <i>Cancers</i> , 2020, 12, 1819.	1.7	69
401	The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094094.	1.4	35
402	Metformin and cancer immunity. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1403-1409.	2.8	54
403	Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma. <i>Immunotherapy</i> , 2020, 12, 983-995.	1.0	6
404	Enhanced Cancer DNA Vaccine <i>via</i> Direct Transfection to Host Dendritic Cells Recruited in Injectable Scaffolds. <i>ACS Nano</i> , 2020, 14, 11623-11636.	7.3	40
405	Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells. <i>Transfusion Medicine and Hemotherapy</i> , 2020, 47, 454-463.	0.7	8
406	Experimental analysis of T cell epitopes for designing liver cancer vaccine predicted by system-level immunoinformatics approach. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G1055-G1069.	1.6	4
407	Identification of Human Secretome and Membrane Proteome-Based Cancer Biomarkers Utilizing Bioinformatics. <i>Journal of Membrane Biology</i> , 2020, 253, 257-270.	1.0	4
408	Th9 Cell Differentiation and Its Dual Effects in Tumor Development. <i>Frontiers in Immunology</i> , 2020, 11, 1026.	2.2	35

#	ARTICLE	IF	CITATIONS
409	Long noncoding RNA loss in immune suppression in cancer. , 2020, 213, 107591.		44
410	Biogenic nanoparticles as immunomodulator for tumor treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1646.	3.3	21
411	Immunomodulatory effects of ablation therapy on tumors: Potentials for combination with immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188385.	3.3	22
412	Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. Frontiers in Immunology, 2020, 11, 249.	2.2	94
413	Identification of immune cells and mRNA associated with prognosis of gastric cancer. BMC Cancer, 2020, 20, 206.	1.1	37
414	Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma. Cancers, 2020, 12, 545.	1.7	27
415	Sex differences in the association between tumor growth and T cell response in a melanoma mouse model. Cancer Immunology, Immunotherapy, 2020, 69, 2157-2162.	2.0	14
416	Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy. ACS Nano, 2020, 14, 9562-9571.	7.3	65
417	Bacteria and cancer: Different sides of the same coin. Life Sciences, 2020, 246, 117398.	2.0	38
418	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clinical Cancer Research, 2020, 26, 1045-1053.	3.2	13
419	PD-1/PD-L1-dependent immune response in colorectal cancer. Journal of Cellular Physiology, 2020, 235, 5461-5475.	2.0	86
420	Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate. International Immunopharmacology, 2020, 84, 106495.	1.7	28
421	Chinese Herbal Medicine and Its Regulatory Effects on Tumor Related T Cells. Frontiers in Pharmacology, 2020, 11, 492.	1.6	23
422	Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Research and Treatment, 2020, 181, 391-401.	1.1	42
423	Positive affect and peripheral inflammatory markers among adults: A narrative review. Psychoneuroendocrinology, 2021, 123, 104892.	1.3	16
424	Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Molecular Therapy, 2021, 29, 555-570.	3.7	130
425	Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. Biomaterials, 2021, 268, 120579.	5.7	46
426	Integrated Bioinformatical Analysis Identifies GIMAP4 as an Immune-Related Prognostic Biomarker Associated With Remodeling in Cervical Cancer Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 637400.	1.8	17

#	ARTICLE	IF	CITATIONS
427	Comprehensive Characterization of Tumor Microenvironment Differences in Cancer between Male and Female Patients. SSRN Electronic Journal, 0, , .	0.4	0
428	Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. Cancer Immunology, Immunotherapy, 2021, 70, 1691-1704.	2.0	6
429	Prognostic Value of Sarcopenia and Systemic Inflammation Markers in Patients Undergoing Definitive Radiotherapy for Esophageal Cancer. Cancer Management and Research, 2021, Volume 13, 181-192.	0.9	16
430	Immunotherapy in colorectal cancer. Advances in Cancer Research, 2021, 151, 137-196.	1.9	18
431	Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted Immunotherapy. Cancer Immunology Research, 2021, 9, 430-440.	1.6	8
432	A Palette of Cytokines to Measure Anti-Tumor Efficacy of T Cell-Based Therapeutics. Cancers, 2021, 13, 821.	1.7	20
433	Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer. Scientific Reports, 2021, 11, 4842.	1.6	4
434	Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors. Cancer Science, 2021, 112, 1390-1401.	1.7	7
435	Anti-inflammatory chemoprevention attenuates the phenotype in a mouse model of esophageal adenocarcinoma. Carcinogenesis, 2021, 42, 1068-1078.	1.3	4
436	The Synergistic Effects of Polysaccharides and Ginsenosides From American Ginseng (Panax) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Barrier Dysfunctions Based on Microbiome-Metabolomics Analysis. Frontiers in Immunology, 2021, 12, 665901.	2.2	61
437	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. Frontiers in Oncology, 2021, 11, 598001.	1.3	3
438	New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. , 2021, 9, e001243.		21
439	All-trans retinoic acid in anticancer therapy: how nanotechnology can enhance its efficacy and resolve its drawbacks. Expert Opinion on Drug Delivery, 2021, 18, 1335-1354.	2.4	7
440	Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). Pharmaceuticals, 2021, 14, 447.	1.7	32
441	Alum colloid encapsulated inside $\beta$ -glucan particles enhance humoral and CTL immune responses of MUC1 vaccine. Chinese Chemical Letters, 2021, 32, 1963-1966.	4.8	8
442	Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Translational Lung Cancer Research, 2021, 10, 2842-2857.	1.3	28
443	Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Research and Treatment, 2021, 190, 5-17.	1.1	16
444	Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy, 2021, 6, 263.	7.1	739

#	ARTICLE	IF	CITATIONS
445	EVALUATION OF IMMUNOGENICITY OF SYNTHETIC NEOANTIGEN PEPTIDES FOR THE MELANOMA VACCINE MODEL. , 2021, 20, 61-68.	0.3	2
446	An immune cell infiltration-related gene signature predicts prognosis for bladder cancer. Scientific Reports, 2021, 11, 16679.	1.6	15
447	Bacteria-based immune therapies for cancer treatment. Seminars in Cancer Biology, 2022, 86, 1163-1178.	4.3	10
448	The therapeutic triad of extracellular vesicles: As drug targets, as drugs, and as drug carriers. Biochemical Pharmacology, 2021, 192, 114714.	2.0	17
449	Th1 polarization in the tumor microenvironment upregulates the myeloid-derived suppressor-like function of macrophages. Cellular Immunology, 2021, 369, 104437.	1.4	8
452	In Vitro Polarization of T-Helper Cells. Methods in Molecular Biology, 2014, 1193, 105-113.	0.4	6
453	Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. , 2014, , 111-121.		2
455	Th9 cells promote antitumor immune responses in vivo. Journal of Clinical Investigation, 2012, 122, 4160-4171.	3.9	303
456	Hypoxia-inducible factors: a central link between inflammation and cancer. Journal of Clinical Investigation, 2016, 126, 3689-3698.	3.9	144
457	Immunological Activity of Vegetable Soup Made by Extruded Radish. Food Engineering Progress, 2018, 22, 161-172.	0.0	1
458	MELOE-1 Antigen Contains Multiple HLA Class II T Cell Epitopes Recognized by Th1 CD4+ T Cells from Melanoma Patients. PLoS ONE, 2012, 7, e51716.	1.1	10
459	Block Copolymer/DNA Vaccination Induces a Strong Allergen-Specific Local Response in a Mouse Model of House Dust Mite Asthma. PLoS ONE, 2014, 9, e85976.	1.1	11
460	XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers. PLoS ONE, 2017, 12, e0186900.	1.1	21
461	Associations between polymorphisms in the IL-4 gene and renal cell carcinoma in Chinese Han population. Oncotarget, 2017, 8, 82078-82084.	0.8	3
462	Cell-mediated immune resistance in cancer. , 2020, 3, 232-251.		9
463	Peptides for Diagnosis and Treatment of Colorectal Cancer. Current Medicinal Chemistry, 2014, 21, 2410-2416.	1.2	21
464	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. Iranian Journal of Basic Medical Sciences, 2020, 23, 1065-1077.	1.0	7
465	Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy, 2009, 1, 599-621.	1.0	62

#	ARTICLE	IF	CITATIONS
466	The Influence of Melatonin on Immune System and Cancer. International Journal of Cancer and Clinical Research, 2015, 2, .	0.1	3
467	Nodal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer. Radiation Oncology Journal, 2016, 34, 305-312.	0.7	9
468	Role of different immune cells and metabolic pathways in modulating the immune response in pancreatic cancer (Review). Molecular Medicine Reports, 2020, 22, 4981-4991.	1.1	10
469	Biomarkers of immunotherapy in non-small cell lung cancer (Review). Oncology Letters, 2020, 20, 1-1.	0.8	8
470	Antitumor activity of interleukin-18 on A549 human lung cancer cell line. Journal of Cancer Research and Therapeutics, 2019, 15, 1635.	0.3	3
471	Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Reports, 2012, 45, 677-685.	1.1	67
472	The Enhanced Effect of Oplopanax elatus Nakai on the Immune System and Antitumor Activity. The Korean Journal of Food and Nutrition, 2013, 26, 375-382.	0.3	4
473	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
474	Hodgkin lymphoma with diplopia and nystagmus: a paraneoplastic cerebellar degeneration with ectopic expression of DNER antigen on Reed-Sternberg cells. Clinical Lymphoma, Myeloma and Leukemia, 2021, . .	0.2	3
475	Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis—Mechanistic Insights into Anemia of Inflammation and Its Treatment. Nutrients, 2021, 13, 3732.	1.7	36
476	Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2021, 9, 738373.	1.8	15
477	Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Molecular Biology Reports, 2021, 48, 8075-8095.	1.0	40
479	TH1/TH2 Cytokine Fingerprinting for Probing Diseases: From the Bench to the Clinic. Journal of Medical Sciences, 2009, 1, 21-27.	0.2	0
480	Counteracting Subversion of MHC Class II Antigen Presentation by Tumors. , 2011, , 173-194.		0
481	The Novel Use of Zwitterionic Bacterial Components and Polysaccharides in Immunotherapy of Cancer and Immunosuppressed Cancer Patients. , 0, , .		0
482	Tumor Immunotherapy by Utilizing a Double-Edged Sword, Chemokines. , 2013, , 97-118.		0
483	Role of Stroma in Disease Progression. , 2013, , 129-147.		0
484	Innate and Adaptive Immune Responses to Cancer. , 2014, , 81-121.		1

#	ARTICLE	IF	CITATIONS
485	Immuno-stimulating Activities of Skipjack Tuna Katsuwonus pelamis Cooking Juice Concentrates on Mouse Macrophages and Spleen Cells. Han'guk Susan Hakhoe Chi = Bulletin of the Korean Fisheries Society, 2014, 47, 776-784.	0.1	3
487	The Cancer Cell Killing Effects of Gynura procumbens, Toleaf Are Associated with CD4+ T Lymphocyte Activation. , 2019, , .		1
488	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3
489	DESIGNING A VACCINE FOR CANCER: A LOOK INTO DENDRITIC CELL CANCER VACCINE. Asian Journal of Pharmaceutical and Clinical Research, 0, , 27-31.	0.3	0
490	Immunopathology as a Basis for Immunotherapy of Head and Neck Squamous Cell Carcinoma. , 2020, , 333-354.		0
491	Spatial Profiles of Intratumoral PD-1+ Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 769534.	2.2	12
492	The role of systemic inflammatory cells in meningiomas. Neurosurgical Review, 2022, 45, 1205-1215.	1.2	9
493	Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nature Biomedical Engineering, 2021, 5, 1261-1273.	11.6	32
494	Tumour-directed microenvironment remodelling at a glance. Journal of Cell Science, 2020, 133, .	1.2	10
495	Tetrameric Fluorescent Antigen Arrays for Single-Step Identification of Antigen-Specific B Cells. Journal of Visualized Experiments, 2020, , .	0.2	2
497	Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Research, 2013, 33, 2047-56.	0.5	55
498	Associations between polymorphisms in the IL-4 and IL-4 receptor genes and urinary carcinomas: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 1227-33.	1.3	8
500	A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 761839.	1.8	24
501	Review of Functionalized Nanomaterials for Photothermal Therapy of Cancers. ACS Applied Nano Materials, 2021, 4, 11353-11385.	2.4	75
502	Synergistic Anti-Tumor Efficacy of Hollow Mesoporous Silica-Based Cancer Vaccine and Immune Checkpoint Inhibitor at Local Site. SSRN Electronic Journal, 0, , .	0.4	0
503	Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer. Technology in Cancer Research and Treatment, 2021, 20, 153303382110521.	0.8	5
504	A Risk Model Composed of Six Immune Genes to Predict the Prognosis and Immunotherapy Response for Gastric Cancer. SSRN Electronic Journal, 0, , .	0.4	0
505	Ferroptosis-related genes identify tumor immune microenvironment characterization for the prediction of prognosis in cervical cancer. Annals of Translational Medicine, 2022, 10, 123-123.	0.7	16

#	ARTICLE	IF	CITATIONS
507	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. <i>Biomolecules</i> , 2022, 12, 132.	1.8	7
508	Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers. <i>Cancers</i> , 2022, 14, 571.	1.7	12
509	Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. <i>Frontiers in Immunology</i> , 2022, 13, 773264.	2.2	15
510	Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. <i>Experientia Supplementum (2012)</i> , 2022, 113, 89-106.	0.5	4
511	Immunomodulatory effects of mixed <i>Lactobacillus plantarum</i> on lipopolysaccharide-induced intestinal injury in mice. <i>Food and Function</i> , 2022, 13, 4914-4929.	2.1	5
512	Immunogenetic mechanisms in the treatment of cancer. , 2022, , 321-338.		0
513	Peptides for Vaccine Development. <i>ACS Applied Bio Materials</i> , 2022, 5, 905-944.	2.3	26
514	IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of Lung Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 857289.	1.6	10
515	The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. <i>Scientific Reports</i> , 2022, 12, 5377.	1.6	16
516	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. <i>Molecular Oncology</i> , 2022, 16, 2153-2173.	2.1	13
518	Xanthohumol: An underestimated, while potent and promising chemotherapeutic agent in cancer treatment. <i>Progress in Biophysics and Molecular Biology</i> , 2022, 172, 3-14.	1.4	12
519	Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site. <i>Acta Biomaterialia</i> , 2022, 145, 235-245.	4.1	13
520	Virus-like particles: a self-assembled toolbox for cancer therapy. <i>Materials Today Chemistry</i> , 2022, 24, 100808.	1.7	7
521	Modulation of the oral glucocorticoid system during black raspberry mediated oral cancer chemoprevention. <i>Carcinogenesis</i> , 2022, 43, 28-39.	1.3	9
536	Chrysin enhances antitumour immunity response through the $IL-12/STAT4$ signal pathway in the $B16F10$ melanoma mouse model. <i>Scandinavian Journal of Immunology</i> , 2022, 96, e13177.	1.3	6
537	Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 844736.	2.2	6
538	The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103729.	2.0	7
539	Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1

#	ARTICLE	IF	CITATIONS
540	Derived Multiple Allogeneic Protein Paracrine Signaling (d-MAPPS) Enhances T Cell-Driven Immune Response to Murine Mammary Carcinoma. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-10.	0.7	0
541	Leukemia derived dendritic cell (DC <sub>leu</sub> ) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells. <i>Immunobiology</i> , 2022, 227, 152237.	0.8	8
542	Characteristics of tumor infiltrating lymphocytes in sinonasal mucosal melanoma and prognosis for patients. <i>Current Problems in Cancer</i> , 2022, 46, 100878.	1.0	4
543	Perspectives and Advances of Nonthermal Plasma Technology in Cancers. <i>IEEE Transactions on Plasma Science</i> , 2022, 50, 2489-2515.	0.6	2
544	Identification of T cell-related biomarkers for breast cancer based on weighted gene co-expression network analysis. <i>Journal of Chemotherapy</i> , 2023, 35, 298-306.	0.7	2
545	The efficient circulating immunoscore predicts prognosis of patients with advanced gastrointestinal cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
546	Prediction of Prognosis in Patients With Endometrial Carcinoma and Immune Microenvironment Estimation Based on Ferroptosis-Related Genes. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	3
547	Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. <i>Cancers</i> , 2022, 14, 3414.	1.7	7
548	A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice. <i>Vaccines</i> , 2022, 10, 1092.	2.1	3
549	Th1-Dominant CD4+ T Cells Orchestrate Endogenous Systematic Antitumor Immune Memory After Cryo-Thermal Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
550	Immune-Endocrine Perspectives of Breast Cancer. , 2022, , 22-61.		0
551	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
552	Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses. <i>ELife</i> , 0, 11, .	2.8	25
553	A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
554	Topical Application of <i>Houttuynia cordata</i> Thunb Ethanol Extracts Increases Tumor Infiltrating CD8+ /Treg Cells Ratio and Inhibits Cutaneous Squamous Cell Carcinoma in vivo. <i>Oncologie</i> , 2022, 24, 565-577.	0.2	1
555	Immunobiology of Testicular Cancer. , 2022, , .		3
556	Utilizing Bacteria-Derived Components for Cancer Immunotherapy. <i>BIO Integration</i> , 2022, 3, .	0.9	1
557	Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1710-1721.	1.9	3

#	ARTICLE	IF	CITATIONS
559	Analysis of Tumor-Infiltrating T-Cell Transcriptomes Reveal a Unique Genetic Signature across Different Types of Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11065.	1.8	4
560	Iridubin regulates T cell differentiation by promoting $\beta$ 28 expression in bone marrow-derived dendritic cells to alleviate inflammatory bowel disease. <i>Phytotherapy Research</i> , 0, , .	2.8	0
561	Compound 511 ameliorates MRSA-induced lung injury by attenuating morphine-induced immunosuppression in mice via PI3K/AKT/mTOR pathway. <i>Phytomedicine</i> , 2023, 108, 154475.	2.3	5
562	Significant Tumor Reduction With Traditional Chinese Medicine in a Patient With Advanced Prostate Cancer: A Case Report. <i>American Journal of Men's Health</i> , 2022, 16, 155798832211308.	0.7	1
564	Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. <i>Cancers</i> , 2022, 14, 5520.	1.7	10
565	Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus. , 2023, 1, 76-86.		4
566	Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunity. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 47, 102628.	1.7	2
568	Evaluation of innate and adaptive immune system interactions in the tumor microenvironment via a 3D continuum model. <i>Journal of Theoretical Biology</i> , 2023, 559, 111383.	0.8	1
569	Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15234.	1.8	1
570	Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15471.	1.8	11
571	HLA expression as a risk factor for metastases of cutaneous squamous-cell carcinoma in organ-transplant recipients. <i>Human Immunology</i> , 2023, 84, 208-213.	1.2	0
572	Improved cancer immunotherapy strategies by nanomedicine. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	7
573	A novel defined TLR3 agonist as an effective vaccine adjuvant. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
574	Effect Model of PD-1 Inhibitors on Immune Metabolism of Mito+ T Lymphocytes in Patients with Non-Small Cell Lung Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 1038-1047.	0.0	0
575	Immune infiltration associated C1q acts as a novel prognostic biomarker of cutaneous melanoma. <i>Medicine (United States)</i> , 2023, 102, e33088.	0.4	0
576	Clinical prognostic value of OSGIN2 in gastric cancer and its proliferative effect in vitro. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
578	Optimizing the manufacturing and antitumour response of CAR-T therapy. , 2023, 1, 271-285.		14
579	Ranitidine as an adjuvant regulates macrophage polarization and activates CTLs through the PI3K-Akt2 signaling pathway. <i>International Immunopharmacology</i> , 2023, 116, 109729.	1.7	2

#	ARTICLE	IF	CITATIONS
580	Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	0
581	Multifaceted Nano-DEV-IL for Sustained Release of IL-12 to Avert the Immunosuppressive Tumor Microenvironment and IL-12-Associated Toxicities. <i>ACS Applied Materials &amp; Interfaces</i> , 2023, 15, 20012-20026.	4.0	3
582	IEDB and CEDAR: Two Sibling Databases to Serve the Global Scientific Community. <i>Methods in Molecular Biology</i> , 2023, , 133-149.	0.4	0
594	Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer. <i>Discover Oncology</i> , 2023, 14, .	0.8	0
595	Regulating metalloimmunology with nanomedicine for cancer therapy. <i>Nano Research</i> , 2023, 16, 13164-13181.	5.8	0
598	Systemic Onco-sphere: Host Adaptive Immune System. , 2023, , 443-468.		0
605	From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy. <i>Histochemistry and Cell Biology</i> , 2024, 161, 299-323.	0.8	1